Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Reports Positive Survival Data from Preclinical Trial of RE-024 for the Treatment of the Ultra-Orphan Disease Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Company to Hold Update Conference Call Today, August 16, 2013 at 10:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has received positive survival results from interim preclinical tests for the Company's compound, RE-024, for the treatment of the
View HTML
Toggle Summary Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management
Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. ( RTRX ), a pharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic
View HTML
Toggle Summary Retrophin Names Marc L. Panoff as Chief Financial Officer
Retrophin Names Marc L. Panoff as Chief Financial Officer New York, NY (May 8, 2013) – Retrophin, Inc. (OTCQB: RTRX) today announced that it has named Marc L. Panoff, CPA, MBA as Chief Financial Officer and Chief Accounting Officer, effective May 20.
View HTML
Toggle Summary Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
Brings wealth of clinical research and regulatory submission expertise to help advance pipeline
View HTML
Toggle Summary Retrophin Sponsors Seventh International NBIA Disorders Association Family Conference
Overview of RE-024 for PKAN presented
View HTML
Toggle Summary Retrophin Announces Positive Results from Preclinical Studies of RE-024 for PKAN
New York, NY (March 11, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced positive results
View HTML
Toggle Summary Retrophin to Present at 25th Annual ROTH Conference
Clinical and corporate updates to be provided March 19 at 2:30 p.m. PT
View HTML
Toggle Summary Retrophin Raises $10.0 Million in Private Placement
Proceeds will be used to advance pipeline of rare-disease drug candidates
View HTML
Toggle Summary Retrophin to Present at the 15th Annual BIO CEO & Investor Conference
Clinical and corporate updates to be shared February 12 at 3:30 p.m.
View HTML
Toggle Summary Retrophin Completes Reverse Merger With Desert Gateway, Inc.
Creates publicly traded biotechnology company
View HTML